

Docket No.: UPAP0002-100

Serial Number: 0359,975

PATENT

Filed: July 23, 1999

1-57. (canceled)


58. (previously amended) A pharmaceutical composition comprising:

a) a polynucleotide function enhancer; and  
 b) A DNA molecule that comprises a DNA sequence that encodes an antigen from an intracellular pathogen; wherein


i) said polynucleotide function enhancer is a compound having one of the following formulas:




or



or



or



wherein:

Ar is benzene, *p*-aminobenzene, *m*-aminobenzene, *o*-aminobenzene, substituted benzene, substituted *p*-aminobenzene, substituted *m*-aminobenzene, substituted *o*-aminobenzene, wherein the amino group in the aminobenzene compounds can be amino, C<sub>1</sub>-C<sub>5</sub> alkylamine, C<sub>1</sub>-C<sub>5</sub>, C<sub>1</sub>-C<sub>5</sub> dialkylamine and substitutions in substituted compounds are halogen, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub> alkoxy;

R<sup>1</sup> is C<sub>1</sub>-C<sub>10</sub> alkyl including branched alkyls;R<sup>2</sup> is C<sub>1</sub>-C<sub>10</sub> alkyl including branched alkyls;R<sup>3</sup> is hydrogen, amine, C<sub>1</sub>-C<sub>5</sub> alkylamine, C<sub>1</sub>-C<sub>5</sub>, C<sub>1</sub>-C<sub>5</sub> dialkylamine

R<sup>2</sup> + R<sup>3</sup> can form a cyclic alkyl, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic alkyl, a cyclic aliphatic amine, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic aliphatic amine, a heterocycle, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted heterocycle including a C<sub>1</sub>-C<sub>10</sub> alkyl N-substituted heterocycle;

R<sup>4</sup> is Ar, R<sup>1</sup> or C<sub>1</sub>-C<sub>5</sub> alkoxy, a cyclic alkyl, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic alkyl, a cyclic aliphatic amine, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic aliphatic amine, a

Docket No.: UPAP0002-100

Serial Number: 09/359,975

PATENT

Filed: July 23, 1999

heterocycle, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted heterocycle and a C<sub>1</sub>-C<sub>10</sub> alkoxy substituted heterocycle including a C<sub>1</sub>-C<sub>10</sub> alkyl N-substituted heterocycle;

R<sup>5</sup> is C=NH;

R<sup>6</sup> is Ar, R<sup>2</sup> or C<sub>1</sub>-C<sub>5</sub> alkoxy, a cyclic alkyl, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic alkyl, a cyclic aliphatic amine, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic aliphatic amine, a heterocycle, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted heterocycle and a C<sub>1</sub>-C<sub>10</sub> alkoxy substituted heterocycle including a C<sub>1</sub>-C<sub>10</sub> alkyl N-substituted heterocycle; and,

R<sup>7</sup> is Ar, R<sup>2</sup> or C<sub>1</sub>-C<sub>5</sub> alkoxy, a cyclic alkyl, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic alkyl, a cyclic aliphatic amine, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic aliphatic amine, a heterocycle, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted heterocycle and a C<sub>1</sub>-C<sub>10</sub> alkoxy substituted heterocycle including a C<sub>1</sub>-C<sub>10</sub> alkyl N-substituted heterocycle; and,

ii) said DNA sequence operatively linked to regulatory sequences which control the expression of said DNA sequence.

59. (original)

The pharmaceutical composition of claim 58 wherein said DNA molecule is a plasmid.

60-62. (canceled)

63. (Previously amended)

The pharmaceutical composition of claim 58 wherein said antigen is a viral antigen.

64. (previously added)

The pharmaceutical composition of claim 63 wherein said pathogen is a virus selected from the group consisting of: human immunodeficiency virus, HIV; Human T cell leukemia virus, HTLV; influenza virus; hepatitis A virus; hepatitis B virus; hepatitis C virus; human papilloma virus, HPV; Herpes simplex 1 virus, HSV1; Herpes simplex 2 virus, HSV2; Cytomegalovirus, CMV; Epstein-Barr virus, EBR; rhinovirus; and, coronavirus.

Docket No.: UPAP0002-100  
PATENT


Serial Number: 09/359,975  
Filed: July 23, 1999

65-114. (canceled)


115. (previously added) A method of introducing DNA molecules into cells of an individual comprising the steps of:

injecting into tissue of said individual at a site on said individual's body, DNA molecules and a polynucleotide function enhancer; wherein

i) said polynucleotide function enhancer is a compound having one of the following formulas:




or



or



or



wherein:

Ar is benzene, *p*-aminobenzene, *m*-aminobenzene, *o*-aminobenzene, substituted benzene, substituted *p*-aminobenzene, substituted *m*-aminobenzene, substituted *o*-aminobenzene, wherein the amino group in the aminobenzene compounds can be amino, C<sub>1</sub>-C<sub>5</sub> alkylamine, C<sub>1</sub>-C<sub>5</sub>, C<sub>1</sub>-C<sub>5</sub> dialkylamine and substitutions in substituted compounds are halogen, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub>

alkoxy;

R<sup>1</sup> is C=O;

R<sup>2</sup> is C<sub>1</sub>-C<sub>10</sub> alkyl including branched alkyls;

R<sup>3</sup> is hydrogen, amine, C<sub>1</sub>-C<sub>5</sub> alkylamine, C<sub>1</sub>-C<sub>5</sub>, C<sub>1</sub>-C<sub>5</sub> dialkylamine;

R<sup>2</sup> + R<sup>3</sup> can form a cyclic alkyl, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic alkyl, a cyclic aliphatic amine, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic aliphatic amine, a heterocycle, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted heterocycle including a C<sub>1</sub>-C<sub>10</sub> alkyl N-substituted heterocycle;

Docket No.: UPAP0002-100

Serial Number: 09/359,975

PATENT

Filed: July 23, 1999

$R^4$  is Ar,  $R^2$  or  $C_1-C_5$  alkoxy, a cyclic alkyl, a  $C_1-C_{10}$  alkyl substituted cyclic alkyl, a cyclic aliphatic amine, a  $C_1-C_{10}$  alkyl substituted cyclic aliphatic amine, a heterocycle, a  $C_1-C_{10}$  alkyl substituted heterocycle and a  $C_1-C_{10}$  alkoxy substituted heterocycle including a  $C_1-C_{10}$  alkyl N-substituted heterocycle;

$R^5$  is  $C=NH$ ;

$R^6$  is Ar,  $R^2$  or  $C_1-C_5$  alkoxy, a cyclic alkyl, a  $C_1-C_{10}$  alkyl substituted cyclic alkyl, a cyclic aliphatic amine, a  $C_1-C_{10}$  alkyl substituted cyclic aliphatic amine, a heterocycle, a  $C_1-C_{10}$  alkyl substituted heterocycle and a  $C_1-C_{10}$  alkoxy substituted heterocycle including a  $C_1-C_{10}$  alkyl N-substituted heterocycle; and,

$R^7$  is Ar,  $R^2$  or  $C_1-C_5$  alkoxy, a cyclic alkyl, a  $C_1-C_{10}$  alkyl substituted cyclic alkyl, a cyclic aliphatic amine, a  $C_1-C_{10}$  alkyl substituted cyclic aliphatic amine, a heterocycle, a  $C_1-C_{10}$  alkyl substituted heterocycle and a  $C_1-C_{10}$  alkoxy substituted heterocycle including a  $C_1-C_{10}$  alkyl N-substituted heterocycle; and,

ii) said DNA molecules are taken up by cells in said tissue.

116. (previously added) The method of claim 115 wherein said DNA molecule comprises a DNA sequence that encodes a protein, said DNA sequence operatively linked to regulatory sequences which control the expression of said DNA sequence.

117. (previously added) The method of claim 115 wherein said DNA molecule is a plasmid.

118. (previously added) The method of claim 115 wherein said tissue includes skin and muscle.

119. (previously added) The method of claim 115 wherein said tissue is skin.

120. (previously added) The method of claim 115 wherein said tissue is muscle.

**Docket No.: UPAP0002-100****Serial Number: 09/359,975****PATENT****Filed: July 23, 1999**

**121. (previously added)** The method of claim 120 wherein said tissue is skeletal muscle.

**122. (previously added)** A pharmaceutical composition according to claim 58, wherein said polynucleotide function enhancer is a compound having the formula  $Ar - R^1 - O - R^2 - R^3$ .

**123. (previously added)** The pharmaceutical composition of claim 122 wherein said DNA molecule is a plasmid.

**124. (previously added)** The pharmaceutical composition of claim 122 wherein said antigen is a viral antigen.

**125. (previously added)** The pharmaceutical composition of claim 124 wherein said pathogen is a virus selected from the group consisting of: human immunodeficiency virus, HIV; Human T cell leukemia virus, HTLV; influenza virus; hepatitis A virus; hepatitis B virus; hepatitis C virus; human papilloma virus, HPV; Herpes simplex 1 virus, HSV1; Herpes simplex 2 virus, HSV2; Cytomegalovirus, CMV; Epstein-Barr virus, EBR; rhinovirus; and, coronavirus.

**126-140 (canceled)**

**141. (previously added)** A method of introducing DNA molecules into cells of an individual according to claim 115, wherein said polynucleotide function enhancer is a compound having the formula  $Ar - R^1 - O - R^2 - R^3$ .

**142. (previously added)** The method of claim 141 wherein said DNA molecule comprises a DNA sequence that encodes a protein, said DNA sequence being operatively linked to regulatory sequences which control the expression of said DNA sequence.


Docket No.: UPA P0002-100

Serial Number: 09/359,975


PATENT

Filed: July 23, 1999


143. (previously added) The method of claim 141 wherein said DNA molecule is a plasmid.
144. (previously added) The method of claim 141 wherein said tissue includes skin and muscle.
145. (previously added) The method of claim 141 wherein said tissue is skin.
146. (previously added) The method of claim 141 wherein said tissue is muscle.
147. (previously added) The method of claim 146 wherein said tissue is skeletal muscle.
148. (previously added) A method of inducing antibodies against an antigen in an individual comprising the steps of:  
     injecting into tissue of said individual at a site on said individual's body, a DNA molecule and a polynucleotide function enhancer,  
     said DNA molecule comprising a DNA sequence that encodes an antigen, said DNA sequence operatively linked to regulatory sequences which control the expression of said DNA sequence,  
     said polynucleotide function enhancer is a compound having one of the following formula:




or



or



or



wherein:

Docket No.: UPAP0 002-100

Serial Number: 09/359,975

PATENT

Filed: July 23, 1999

Ar is benzene, *p*-aminobenzene, *m*-aminobenzene, *o*-aminobenzene, substituted benzene, substituted *p*-aminobenzene, substituted *m*-aminobenzene, substituted *o*-aminobenzene, wherein the amino group in the aminobenzene compounds can be amino, C<sub>1</sub>-C<sub>5</sub> alkylamine, C<sub>1</sub>-C<sub>5</sub> C<sub>1</sub>-C<sub>5</sub> dialkylamine and substitutions in substituted compounds are halogen, C<sub>1</sub>-C<sub>5</sub> alkyl and C<sub>1</sub>-C<sub>5</sub> alkoxy;

R<sup>1</sup> is C=O;

R<sup>2</sup> is C<sub>1</sub>-C<sub>10</sub> alkyl including branched alkyls;

R<sup>3</sup> is hydrogen, amine, C<sub>1</sub>-C<sub>5</sub> alkylamine, C<sub>1</sub>-C<sub>5</sub>, C<sub>1</sub>-C<sub>5</sub> dialkylamine;

R<sup>2</sup> + R<sup>3</sup> can form a cyclic alkyl, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic alkyl, a cyclic aliphatic amine, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic aliphatic amine, a heterocycle, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted heterocycle including a C<sub>1</sub>-C<sub>10</sub> alkyl N-substituted heterocycle;

R<sup>4</sup> is Ar, R<sup>2</sup> or C<sub>1</sub>-C<sub>5</sub> alkoxy, a cyclic alkyl, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic alkyl, a cyclic aliphatic amine, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic aliphatic amine, a heterocycle, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted heterocycle and a C<sub>1</sub>-C<sub>10</sub> alkoxy substituted heterocycle including a C<sub>1</sub>-C<sub>10</sub> alkyl N-substituted heterocycle;

R<sup>5</sup> is C=NH;

R<sup>6</sup> is Ar, R<sup>2</sup> or C<sub>1</sub>-C<sub>5</sub> alkoxy, a cyclic alkyl, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic alkyl, a cyclic aliphatic amine, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic aliphatic amine, a heterocycle, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted heterocycle and a C<sub>1</sub>-C<sub>10</sub> alkoxy substituted heterocycle including a C<sub>1</sub>-C<sub>10</sub> alkyl N-substituted heterocycle; and,

R<sup>7</sup> is Ar, R<sup>2</sup> or C<sub>1</sub>-C<sub>5</sub> alkoxy, a cyclic alkyl, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic alkyl, a cyclic aliphatic amine, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted cyclic aliphatic amine, a heterocycle, a C<sub>1</sub>-C<sub>10</sub> alkyl substituted heterocycle and a C<sub>1</sub>-C<sub>10</sub> alkoxy substituted heterocycle including a C<sub>1</sub>-C<sub>10</sub> alkyl N-substituted heterocycle; and,

wherein said DNA molecule is taken up by cells in said tissue, said DNA sequence is expressed in said cells and an immune response is generated against said antigen.

Docket No.: UPAP000 100  
PATENT

Serial Number: 09/359,975

Filed: July 23, 1999

149. (previously added) The method of claim 148 wherein said polynucleotide function enhancer is a compound having the formula  $Ar - R^1 - O - R^2 - R^3$ .

150. (previously added) The method of claim 148 wherein said DNA molecule is a plasmid.

151. (previously added) The method of claim 148 wherein said antigen is an intracellular pathogen antigen.

152. (previously added) The method of claim 148 wherein said antigen is a viral antigen.

153. (previously added) The method of claim 152 wherein said viral antigen is of a virus selected from the group consisting of: human immunodeficiency virus, HIV; Human T cell leukemia virus, HTLV; influenza virus; hepatitis A virus; hepatitis B virus; hepatitis C virus; human papilloma virus, HPV; Herpes simplex 1 virus, HSV1; Herpes simplex 2 virus, HSV2; Cytomegalovirus, CMV; Epstein-Barr virus, EBR; rhinovirus; and, coronavirus.

154. (previously added) The method of claim 148 wherein said tissue includes skin and muscle.

155. (previously added) The method of claim 154 wherein said tissue is skin.

156. (previously added) The method of claim 154 wherein said tissue is muscle.

157. (previously added) The method of claim 156 wherein said tissue is skeletal muscle.

158. (new) The method of claim 149 wherein said DNA molecule is a plasmid.



**Docket No.: UPAP0002-100**

**Serial Number: 01/359,975**

**PATENT**

**Filed: July 13, 1999**

**159. (new)** The method of claim 149 wherein said antigen is an intracellular pathogen antigen.

**160. (new)** The method of claim 149 wherein said antigen is a viral antigen.

**161. (new)** The method of claim 160 wherein said viral antigen is of a virus selected from the group consisting of: human immunodeficiency virus, HIV; Human T cell leukemia virus, HTLV; influenza virus; hepatitis A virus; hepatitis B virus; hepatitis C virus; human papilloma virus, HPV; Herpes simplex 1 virus, HSV1; Herpes simplex 2 virus, HSV2; Cytomegalovirus, CMV; Epstein-Barr virus, EBR; rhinovirus; and, coronavirus.

**162. (new)** The method of claim 149 wherein said tissue includes skin and muscle.

**163. (new)** The method of claim 162 wherein said tissue is skin.

**164. (new)** The method of claim 162 wherein said tissue is muscle.

**165. (new)** The method of claim 164 wherein said tissue is skeletal muscle.